- Home
- DLO vs ZLAB Comparison
DLO vs ZLAB Comparison
Compare DLO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLO
- ZLAB
- Stock Information
- Founded
- DLO 2013
- ZLAB 2013
- Country
- DLO Uruguay
- ZLAB China
- Employees
- DLO N/A
- ZLAB N/A
- Industry
- DLO Business Services
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- DLO Consumer Discretionary
- ZLAB Health Care
- Exchange
- DLO Nasdaq
- ZLAB Nasdaq
- Market Cap
- DLO 4.0B
- ZLAB 3.2B
- IPO Year
- DLO 2021
- ZLAB 2017
- Fundamental
- Price
- DLO $15.51
- ZLAB $25.41
- Analyst Decision
- DLO Buy
- ZLAB Buy
- Analyst Count
- DLO 9
- ZLAB 6
- Target Price
- DLO $15.00
- ZLAB $57.22
- AVG Volume (30 Days)
- DLO 2.4M
- ZLAB 668.1K
- Earning Date
- DLO 11-12-2025
- ZLAB 11-06-2025
- Dividend Yield
- DLO 3.29%
- ZLAB N/A
- EPS Growth
- DLO 9.30
- ZLAB N/A
- EPS
- DLO 0.48
- ZLAB N/A
- Revenue
- DLO $863,482,000.00
- ZLAB $427,799,000.00
- Revenue This Year
- DLO $38.48
- ZLAB $41.80
- Revenue Next Year
- DLO $27.49
- ZLAB $49.93
- P/E Ratio
- DLO $32.33
- ZLAB N/A
- Revenue Growth
- DLO 22.02
- ZLAB 32.56
- 52 Week Low
- DLO $7.61
- ZLAB $23.82
- 52 Week High
- DLO $16.78
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- DLO 58.83
- ZLAB 27.79
- Support Level
- DLO $14.46
- ZLAB $27.81
- Resistance Level
- DLO $15.88
- ZLAB $29.77
- Average True Range (ATR)
- DLO 0.86
- ZLAB 1.25
- MACD
- DLO 0.01
- ZLAB -0.46
- Stochastic Oscillator
- DLO 61.04
- ZLAB 1.20
About DLO DLocal Limited
DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company's geographical segments include Latin America and Non-Latin America with a majority of its revenue being generated from Brazil in Latin America region.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.